53
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

, , , &
Pages 955-957 | Published online: 24 Apr 2015

References

  • HeoSKNohEKYoonDJJoJCParkJHKimHDasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacityPLoS One201492e9885924918603
  • JabbourELiptonJHA critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phaseClin Lymphoma Myeloma Leuk201313664665624095296
  • AguileraDGTsimberidouAMDasatinib in chronic myeloid leukemia: a reviewTher Clin Risk Manag20095228128919536317
  • AlimenaGBrecciaMLatagliataRDasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizationsLeuk Res2009338e134e13619286256
  • CortesJRousselotPKimDWDasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisBlood200710983207321317185463
  • GuilhotFApperleyJKimDWDasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood2007109104143415017264298
  • LindauerMHochhausADasatinibRecent Results Cancer Res (Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer)20142012765
  • Quintas-CardamaADe Souza SantosFPKantarjianHDynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failureCancer2009115173935394319517473
  • ZwaanCMRizzariCMechinaudFDasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortiumJ Clin Oncol201331192460246823715577
  • KeatingGMLyseng-WilliamsonKAMcCormackPLKeamSJDasatinib: a guide to its use in chronic myeloid leukemia in the EUBio Drugs2013273275279
  • EghtedarAKantarjianHJabbourEOutcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaClin Lymphoma Myeloma Leuk201313447748423770156
  • KrauthMTHerndlhoferSSchmookMTMitterbauer-HohendannerGSchloglEValentPExtensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyHaematologica201196116316620934998
  • HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
  • CortesJKimDWRaffouxEEfficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseLeukemia200822122176218318754032